

RESEARCH ARTICLE

Open Access



Associations between types and sources of dietary carbohydrates and cardiovascular disease risk: a prospective cohort study of UK Biobank participants

Rebecca K. Kelly^{1*}, Tammy Y. N. Tong¹, Cody Z. Watling¹, Andrew Reynolds², Carmen Piernas³, Julie A. Schmidt^{1,4}, Keren Papier¹, Jennifer L. Carter⁵, Timothy J. Key¹ and Aurora Perez-Cornago¹

Abstract

Background Recent studies have reported that the associations between dietary carbohydrates and cardiovascular disease (CVD) may depend on the quality, rather than the quantity, of carbohydrates consumed. This study aimed to assess the associations between types and sources of dietary carbohydrates and CVD incidence. A secondary aim was to examine the associations of carbohydrate intakes with triglycerides within lipoprotein subclasses.

Methods A total of 110,497 UK Biobank participants with \geq two (maximum five) 24-h dietary assessments who were free from CVD and diabetes at baseline were included. Multivariable-adjusted Cox regressions were used to estimate risks of incident total CVD (4188 cases), ischaemic heart disease (IHD; 3138) and stroke (1124) by carbohydrate intakes over a median follow-up time of 9.4 years, and the effect of modelled dietary substitutions. The associations of carbohydrate intakes with plasma triglycerides within lipoprotein subclasses as measured by nuclear magnetic resonance (NMR) spectroscopy were examined in 26,095 participants with baseline NMR spectroscopy measurements.

Results Total carbohydrate intake was not associated with CVD outcomes. Free sugar intake was positively associated with total CVD (HR; 95% CI per 5% of energy, 1.07;1.03–1.10), IHD (1.06;1.02–1.10), and stroke (1.10;1.04–1.17). Fibre intake was inversely associated with total CVD (HR; 95% CI per 5 g/d, 0.96;0.93–0.99). Modelled isoenergetic substitution of 5% of energy from refined grain starch with wholegrain starch was inversely associated with total CVD (0.94;0.91–0.98) and IHD (0.94;0.90–0.98), and substitution of free sugars with non-free sugars was inversely associated with total CVD (0.95;0.92–0.98) and stroke (0.91;0.86–0.97). Free sugar intake was positively associated with triglycerides within all lipoproteins.

Conclusions Higher free sugar intake was associated with higher CVD incidence and higher triglyceride concentrations within all lipoproteins. Higher fibre intake and replacement of refined grain starch and free sugars with wholegrain starch and non-free sugars, respectively, may be protective for incident CVD.

Keywords Coronary heart disease, Stroke, Nutritional epidemiology, Primary prevention, Carbohydrates

*Correspondence:

Rebecca K. Kelly
rebecca.kelly@ndph.ox.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Cardiovascular disease (CVD) is the leading cause of death worldwide [1]. Evidence from randomised controlled trials (RCTs) and observational studies suggests that total carbohydrate intakes are neither harmful nor beneficial to cardiovascular health [2–4]. However, recent studies suggest that carbohydrate quality may be a more important determinant of CVD outcomes than carbohydrate quantity [3].

Carbohydrates are classified chemically as monosaccharides and disaccharides (sugars), polyols, oligosaccharides, and polysaccharides (starch and non-starch) [2]. Sugars may be further categorised as free sugars (all monosaccharides and disaccharides added to foods by the manufacturer, cook or consumer, plus sugars naturally present in honey, syrups, and unsweetened fruit juices) or non-free sugars (all sugars excluded from the definition for free sugars, mostly naturally occurring in fruit, vegetables, and dairy products) [2, 5]. Public health bodies recommend limiting free sugar [2, 6] or added sugar [7] intake to ~5–10% of total daily energy intake based on meta-analyses of RCTs in adults showing that reducing free sugar intake in an ad libitum diet reduces total energy intake, which may relate to lower body weight [2, 8]. Moreover, in a recent UK Biobank study, we found that free sugar intake was associated with higher triglyceride concentrations [9], which Mendelian randomisation (MR) studies have suggested have a causal association with ischaemic heart disease (IHD) [10, 11], although it is unknown whether these associations depend on the transporting lipoprotein particle. While meta-analyses of observational studies have found that intake of sugar-sweetened beverages (SSBs) is associated with IHD [12–15], the associations between total dietary free sugars and risk of CVD and CVD subtypes remain unclear [2, 16, 17].

Findings from a recent meta-analysis of observational studies suggest that higher intakes of wholegrain foods and fibre are associated with lower risk of IHD, although evidence is limited for stroke risk [18]. Increasing fibre and wholegrain food intake improves cardiometabolic risk markers (e.g. adiposity and blood pressure) in RCTs [18]. Whereas higher risks of total CVD and stroke were observed among participants in the highest category of refined grain food intake in a recent large observational study [19].

The primary aim of this study was to investigate the prospective associations of types and sources of carbohydrates with risks of total CVD, IHD and total stroke, and the role of dietary substitutions in these associations. A secondary aim was to examine the associations of carbohydrate intakes with plasma triglycerides in different lipoprotein subclasses as determined by nuclear magnetic resonance (NMR) spectroscopy.

Methods

Study design and participants

UK Biobank is a prospective cohort study of 503,317 men and women aged 37 to 73 years recruited between 2006 and 2010 [20]. Eligible adults living within 25 miles of 22 assessment centres across England, Wales and Scotland (9.2 million) were identified from National Health Service (NHS) registers and invited to participate (response rate 5.5%). At baseline, participants provided detailed information on lifestyle and sociodemographic factors via a self-administered touchscreen questionnaire and interview, and physical measurements and biological samples were collected using standardised procedures (see Additional file 1: Supplemental methods). The UK Biobank was approved by the NHS North West Multicentre Research Ethics Committee (approval letter dated 29th of June 2021, reference 21/NW/0157), and all participants provided informed consent to participate and be followed through linkage to their health records. Further details regarding the study protocol and data access for researchers have been published elsewhere [21].

Assessment of carbohydrate intakes

Diet was measured using the Oxford WebQ questionnaire, an online 24-h dietary assessment [22]. This questionnaire was recently validated against energy expenditure measured by accelerometry and biomarkers for total sugar intake and found to perform well compared with traditional interviewer-administered 24-h dietary recalls [23]. Participants recruited between April 2009 and September 2010 completed the 24-h dietary assessment at the assessment centre. Participants who provided a valid email address at recruitment were invited to complete identical 24-h dietary assessments on four further occasions between February 2011 and April 2012 (Additional file 1 Fig. S1).

Intakes of 206 food items and 32 beverages were calculated from responses to each 24-h dietary assessment. Carbohydrate intakes were calculated by multiplying the carbohydrate content of food items and beverages by the frequency of intake using the UK Nutrient Databank food composition tables [24]. Types of carbohydrates calculated included total sugars, which were further separated into free sugars and non-free sugars (total sugars minus free sugars) [5], and fibre (non-starch polysaccharides [NSPs] measured using the Englyst method) [24, 25]. Sources of carbohydrates were also calculated as follows: refined grain starch (starch content of white bread, white pasta and rice, other cereals, pizza, samosas, pakoras, grain dishes with added fat, savoury snacks, savoury crackers,

biscuits, cakes, pastries and desserts), and wholegrain starch (starch content of brown seeded and wholemeal bread, wholemeal pasta and brown rice, bran cereal, biscuit cereal, oat cereal and muesli) [26]. The starch content of wholegrain and refined grain foods were calculated to approximate the amount of wholegrain and refined grains consumed, as starch is the primary component of wheat grains [27]. Intakes of carbohydrates were calculated from the average of \geq two (maximum of five) 24-h dietary assessments to minimise the effects of random error and within-person variability [9, 28]. See Additional file 1 Table S1 for further details on the food items and beverages used to calculate carbohydrate types and sources.

Ascertainment of cardiovascular disease outcomes

Information on date and cause for hospital admission were coded from linkage to Health Episode Statistics for English participants, the Patient Episode Database for Welsh participants, and Scottish Morbidity Records for Scottish participants. Date and cause of death were provided by the NHS Information Centre for English and Welsh participants and NHS Central Register Scotland for Scottish participants' death certificates. At the time of our analyses, hospital admission data were available up until 30th of September 2021 for England, 31st of July 2021 for Scotland, and 28th of February 2018 for Wales, and death data were available up until 30th of September 2021 for England and Wales, and 31st of October 2021 for Scotland. Therefore, we censored analyses for all outcomes at the earliest censoring date for each country.

Primary outcomes were IHD, defined as a primary diagnosis of incident (fatal or non-fatal) IHD (ICD-10 [international classification of diseases, 10th revision] codes I21-I25) or coronary revascularisation (OPCS-4 [Classification of Interventions and Procedures, 4th revision] codes K49-K50, K75, K40-K46); total stroke, defined as primary diagnosis of incident (fatal or non-fatal) ischaemic or haemorrhagic stroke (ICD-10 codes I60-I61, I63-I64); and total CVD, defined as a primary diagnosis of incidental (fatal or non-fatal) IHD or total stroke (see Additional file 1 Table S2) [29–32]. We performed secondary analyses for IHD and stroke subtypes, including acute myocardial infarction (AMI; ICD-10 I21), ischaemic stroke (ICD-10 I63), and haemorrhagic stroke (ICD-10 I60-I61).

Measurement of triglycerides in lipoprotein subclasses

Lipids and other metabolic measures (168 absolute levels and 81 ratios) were quantified from a random subset of ~118,000 non-fasting plasma samples obtained from UK Biobank participants at baseline (2006–2010)

using high-throughput NMR spectroscopy (Nightingale Health Ltd., Helsinki, Finland) [33]. In a recent UK Biobank study of macronutrient intakes and serum lipids measured by clinical chemistry [9], carbohydrate intakes were most strongly associated with total triglycerides, although it remains unclear whether these associations diverge for triglycerides within different lipoprotein subclasses [10, 34]. The Nightingale NMR platform provided simultaneous quantification of total triglyceride concentrations and triglyceride concentrations within 17 lipoprotein subclasses. Triglyceride measurements with $\geq 20\%$ of values below the limit of quantification (LOQ) were excluded ($n=1$) and values below the LOQ were set to half the minimum lowest measured value for that triglyceride measurement (Additional file 1 Table S3) [35, 36]. Therefore, total triglyceride concentrations and triglyceride concentrations within 16 lipoprotein subclasses were included in this study. Non-fasting blood collection procedures are described in detail elsewhere [37], and further information on NMR spectroscopy measurements and quality control can be found in Additional file 1 Supplemental methods.

Exclusion criteria

Participants were excluded if they withdrew consent from the study ($n=904$), had prevalent CVD prior to their most recent 24-h dietary assessment ($n=9132$), or diabetes at recruitment (either self-reported diabetes diagnosis or were taking medication for diabetes; $n=3759$), or they did not complete \geq two 24-h dietary assessments ($n=376,074$; see Fig. 1). Participants were also excluded if they did not have \geq two 24-h dietary assessments after excluding dietary assessments with extreme energy intakes (outside the range of 3347 to 17573 kJ, or 800 to 4200 kcal/d for men, outside the range of 2092 to 14,644 kJ, or 500 to 3500 kcal/d for women [38]; $n=2140$) or where participants reported they were ill or fasting on the day of dietary assessment ($n=811$). The main prospective analyses included a total of 110,497 participants who completed on average 2.9 (SD 0.9) 24-h dietary assessments. For the observational analyses of carbohydrate intakes and triglycerides, participants were further excluded if they were missing values for one or more triglyceride measurements ($n=84,402$), leaving a total of 26,095 participants available for these analyses.

Statistical analysis

Carbohydrate intakes were expressed as a percentage of total energy intake, except for fibre which was expressed in grams per day (g/d), and each were categorised into quartiles. The baseline characteristics of participants




Fig. 1 Flow chart of participants included in the sample for the main prospective analyses ($n=110,497$) and the observational analyses of plasma total triglycerides and triglycerides in lipoprotein subclasses ($n=26,095$). *Abbreviations:* CVD cardiovascular disease

were described by highest and lowest quartiles of total carbohydrate, free sugar, and fibre intakes.

Cox proportional hazards regression, with age as the underlying time variable, was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between quartiles of carbohydrate intakes and CVD incidence. Carbohydrate intakes were also modelled continuously in increments of 5% higher energy intake except for fibre intake, which was modelled in increments of 5 g/d higher intake. Potential non-linear associations were assessed by using likelihood ratio (LR) tests comparing the model with quartiles of carbohydrates intake treated as ordered categorical variables to a model with quartiles of carbohydrate intakes treated as continuous variables. Tests for linear trend were performed using the continuous (per increment) values for carbohydrate intakes. We tested the proportional hazards assumption on the basis of Schoenfeld residuals, and this was not violated for exposures and covariates of interest in our multivariable models for any outcome.

We estimated participant survival time from age at last completed 24-h dietary assessment until age at last follow-up, first diagnosis of CVD outcome, loss to follow-up or death, whichever occurred first. The minimally adjusted model was stratified by age at recruitment (<45, 45–49, 50–54, 55–59, 60–64, ≥ 65 years) and sex, and adjusted for recruitment region (London, North West England, North-Eastern England, Yorkshire & the Humber, West Midlands, East Midlands, South-East England, South-West England, Wales & Scotland). Multivariable models were further adjusted for ethnicity (white, mixed, Asian or Asian British, black or black British, other, unknown), Townsend deprivation index (quintiles from least to most deprived, unknown), education (college/university degree or vocational qualification, national examination at 17–18 years of age, national examination at 16 years of age, unknown), alcohol intake (0.1–0.9 g/d, 1–4.9 g/d, 5–14.9 g/d, ≥ 15 g/d, or none for women, and 0.1–0.9 g/d, 1–4.9 g/d, 5–29.9 g/d, ≥ 30 g/d, or none for men), smoking status (never, former, light smokers [<15 cigarettes/d], medium to heavy

smokers [≥ 15 cigarettes/d], smoker of unknown number of cigarettes, unknown), physical activity (low, medium or high according to excess metabolic equivalent task [MET] hours/week, unknown), menopausal status at recruitment among women only (pre-menopausal, post-menopausal, unknown), body mass index (BMI; <20, 20–22.49, 22.5–24.9, 25.0–27.49, 27.5–29.9, 30–32.49, 32.5–34.9, ≥ 35 kg/m², unknown), saturated fatty acid (SFA) intake (quintiles of % of energy intake), and average daily energy intake (sex-specific quintiles of kJ/d). Multivariable models were also adjusted for fruit and vegetable intake (quintiles of g/d) as a marker of healthy diet, excepting for models with total sugars, non-free sugars, and fibre because whole fruit and vegetables are a major source of these exposures and therefore introduce collinearity.

We also examined the role of other key cardiometabolic risk factors in supplemental analyses, including waist circumference, systolic blood pressure, serum lipids measured by clinical chemistry (LDL cholesterol [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, apolipoprotein B [ApoB]), and glycated haemoglobin (HbA1c); however, because these were potential physiological mediators, they were not included in the final models. While we examined other dietary factors (i.e. polyunsaturated fatty acids, monounsaturated fatty acids and trans fatty acids) and women-specific variables (i.e. menopausal hormonal therapy, oral contraceptive pill use, and parity) as potential covariates, these did not have any effects on the model and were therefore not included in the final models. Dietary covariates (i.e. total energy, fruit and vegetable, and SFA intakes) were calculated from responses to \geq two 24-h dietary assessments (2009–2012), and all other covariates were defined from questionnaire and interview data and physical measurements collected at the UK Biobank assessment centre visit at recruitment (2006–2010). See Additional file 1 Supplemental methods for further details on covariate definitions.

Analyses of dietary substitution

In modelled isoenergetic substitution analyses, we estimated the risks of CVD outcomes when 5% of energy from refined grain starch was replaced with wholegrain starch, or 5% of energy from free sugars was replaced with non-free sugars. Models included energy from all other carbohydrates (i.e. energy from total carbohydrates minus energy from free sugars or refined grain starch), energy from protein, energy from fats, and total energy. Therefore, regression coefficients can be interpreted as the estimated effect of replacing refined grain starch or free sugars with wholegrain starch or non-free sugars, respectively [38].

Observational analyses of triglycerides in lipoprotein subclasses

For carbohydrate types or sources that were significantly associated with CVD risks in our main analyses, and were also significantly associated with triglycerides measured by clinical chemistry in our prior analyses of UK Biobank [9], we assessed their associations with concentrations of plasma total triglycerides and triglycerides in lipoprotein subclasses in a subsample of participants with baseline NMR spectroscopy measurements ($n=26,095$; see Fig. 1). We calculated the geometric means (with 95% CI) of triglyceride measurements. Multivariable linear regression models adjusted for the same covariates as our main Cox regression models were used to examine the associations between the carbohydrate of interest and each log-transformed triglyceride measurement. We exponentiated the regression coefficients, subtracted one from this number, and multiplied by 100 to obtain the estimated percentage difference in triglyceride concentrations per each higher increment of carbohydrate intake. Further details on metabolite analyses can be found in Additional file 1 Supplemental methods.

Sensitivity and subgroup analyses

The robustness of our prospective findings was examined in sensitivity analyses by restricting to participants with (i) \geq three 24-h dietary assessments ($n=67,218$), and (ii) ≥ 2 years of follow-up ($n=109,682$). We also conducted a sensitivity analysis using absolute intakes of refined grain foods and wholegrain foods in grams per day as exposures. Heterogeneity in associations across subgroups of sex, BMI (\sim median, <26, ≥ 26 kg/m²), and smoking status (never smoker, ever smoker) was assessed by including an interaction term between the subgroup and exposure of interest in the Cox model and testing for statistical significance using a LR test.

LR χ^2 statistics were obtained by comparing the Cox regression models with and without the exposure of interest (i.e. carbohydrate intakes) as a measure of the extent to which each exposure predicted CVD risks in different models [39]. The percentage change in the LR χ^2 statistic after adjustment for covariates was calculated using the minimally adjusted model as the reference, with large reductions suggesting that part of any remaining associations may be due to residual confounding [39]. All tests of significance were two-sided, and the Benjamini-Hochberg method was used to control the false discovery rate (FDR) with the alpha set to 0.05 to determine P -values that survived multiple testing [40]. All analyses were conducted using Stata version 17.0 (Stata Corp, TX, United States), and figures were created using R 4.1.2 (R Core Team, Vienna, Austria).

Results

Participant characteristics

Participant characteristics by quartiles of total carbohydrate, free sugar, and fibre intakes are displayed in Table 1 (see Additional file 1 Tables S4-S6 for characteristics across all quartiles). Participants with the highest intakes of total carbohydrate had lower alcohol intakes, total energy intakes, SBP, BMI, and waist

circumference, and a higher proportion were women, and a lower proportion were current smokers. Participants with the highest intakes of free sugar had higher total energy intake, waist circumference, and total triglyceride concentrations (measured by clinical chemistry), and a higher proportion were men and current smokers. Whereas the highest consumers of fibre had higher total energy intake, as well as lower BMI, waist

Table 1 Baseline characteristics across lowest and highest quartiles total carbohydrate, free sugar, and fibre intakes in 110,497 UK Biobank participants

Characteristics	Total carbohydrate intake		Free sugar intake		Fibre intake	
	Q1	Q4	Q1	Q4	Q1	Q4
N	27,625	27,624	27,625	27,624	27,625	27,624
Intake of carbohydrate of interest ^a	39.9 (4.6)	58.3 (3.5)	5.9 (1.7)	17.9 (3.6)	11.3 (2.1)	25.3 (4.1)
Sociodemographic characteristics						
Age at recruitment	55.7 (7.7)	55.6 (8.0)	55.9 (7.6)	55.2 (8.1)	54.6 (7.8)	56.5 (7.8)
Female sex, n (%)	15,111 (54.7%)	16,700 (60.5%)	18,388 (66.6%)	13,511 (48.9%)	16,552 (59.9%)	14,537 (52.6%)
White ethnicity, n (%)	26,929 (97.8%)	26,313 (95.5%)	26,732 (97.1%)	26,448 (96.1%)	26,423 (96.0%)	26,806 (97.4%)
Most affluent, n (%) ^b	5841 (21.1%)	5903 (21.4%)	5895 (21.3%)	5988 (21.7%)	5804 (21.0%)	6055 (21.9%)
College or university degree, n (%)	20,760 (79.2%)	20,006 (78.3%)	20,550 (79.1%)	19,740 (76.8%)	18,971 (74.1%)	21,455 (82.3%)
Lifestyle						
Alcohol (g/d) ^c	24.43 (20.73)	9.55 (11.84)	15.67 (15.88)	16.55 (18.90)	18.84 (19.58)	14.24 (15.20)
Current smoker, n (%)	2755 (10.0%)	1344 (4.9%)	1801 (6.5%)	2480 (9.0%)	2941 (10.7%)	1292 (4.7%)
Physical activity (excess MET h/wk)	37.0 (38.2)	40.7 (41.7)	38.0 (38.5)	39.3 (42.1)	34.5 (38.4)	44.8 (43.1)
Energy intake (kJ/d)	8782 (2033)	8187 (1851)	8088 (1850)	8895 (2,005)	7387 (1,612)	9831 (1,905)
SFA intake (% energy intake)	12.8 (3.1)	10.0 (2.4)	11.4 (3.1)	11.6 (2.9)	12.2 (3.1)	10.9 (2.7)
Fruit and vegetable intake (g/d)	327.6 (197.6)	453.8 (256.0)	450.5 (253.7)	318.8 (196.7)	221.3 (126.8)	579.0 (256.8)
Medical history						
Statin use, n (%)	2573 (9.3%)	2314 (8.4%)	2264 (8.2%)	2476 (9.0%)	2432 (8.8%)	2296 (8.3%)
Post-menopausal, n (%) ^d	10,234 (71.8%)	11,316 (72.0%)	12,859 (73.6%)	8698 (69.1%)	10,503 (68.0%)	10,508 (75.7%)
Biological measurements						
BMI (kg/m ²)	26.9 (4.4)	26.2 (4.4)	26.6 (4.6)	26.5 (4.3)	26.9 (4.5)	25.9 (4.3)
Waist circumference (cm)	89.1 (13.0)	86.3 (12.6)	86.8 (13.0)	88.8 (12.6)	88.4 (13.0)	87.0 (12.6)
SBP (mmHg)	137.2 (18.3)	135.9 (18.5)	135.9 (18.4)	136.7 (18.3)	136.1 (18.3)	136.6 (18.3)
LDL-C (mmol/L) ^e	3.66 (0.83)	3.59 (0.82)	3.62 (0.82)	3.63 (0.82)	3.67 (0.83)	3.57 (0.80)
HDL-C (mmol/L) ^e	1.58 (0.41)	1.45 (0.36)	1.56 (0.39)	1.44 (0.37)	1.52 (0.40)	1.49 (0.37)
Triglycerides (mmol/L) ^e	1.62 (0.96)	1.67 (0.96)	1.55 (0.90)	1.76 (1.02)	1.66 (0.98)	1.63 (0.94)
ApoB (mmol/L) ^e	1.05 (0.23)	1.03 (0.23)	1.04 (0.23)	1.05 (0.23)	1.06 (0.23)	1.03 (0.22)
HbA1c (mmol/mol)	34.7 (4.5)	34.7 (4.2)	34.8 (4.7)	34.7 (4.1)	34.6 (4.1)	34.8 (4.2)

Numbers are means (SD) unless otherwise specified as numbers (%), with % representing the column percentage estimated excluding participants with missing responses

See Additional file 1 Tables S4-S6 for participant characteristics across all quartiles.

Abbreviations: Apo apolipoprotein, BMI body mass index, h/wk hours per week, HbA1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, kg/m² kilogram per square metre, kJ kilojoules, LDL-C low-density lipoprotein cholesterol, MET metabolic equivalent task, mmHg millimetres of mercury, mmol/L millimoles per litre, mmol/mol millimoles per mol, Q quartile, SBP systolic blood pressure, SD standard deviation, SFA saturated fatty acid

^a Expressed as a percentage of energy intake except for fibre, which is expressed in grams per day. Ranges of carbohydrate intake within each quartile are shown in Table S7 (Additional file 1)

^b Participants categorised in the lowest quintile of the Townsend deprivation index (i.e. least deprived)

^c Excluding never drinkers

^d In women only

^e Measured from serum using standard clinical chemistry assays

circumference, and LDL-C concentrations, and a lower proportion were current smokers. Mean intakes and main food sources of carbohydrate intakes are shown in Additional file 1 Tables S7-S8 and Fig. S2, respectively.

Associations of carbohydrate intakes with cardiovascular disease risk

During a median follow-up of 9.4 years, there were 4188, 3138, and 1124 cases of incident total CVD, IHD, and total stroke, respectively. Intake of free sugars was positively associated with total CVD (HR per 5% of energy 1.07; 95% CI 1.03–1.10; *P*-trend<0.001), IHD (1.06; 1.02–1.10; *P*-trend=0.003), and total stroke (1.10; 1.04–1.17; *P*-trend=0.002) risks (Fig. 2). Fibre intake was inversely associated with risk of total CVD (HR per 5 g/d 0.96; 95% CI 0.93–0.99; *P*-trend=0.014). We observed similar directions of association in our analyses of intakes by quartiles, although associations were non-significant for IHD and total CVD in the highest quartile of free sugar intake and fibre intake, respectively (Table 2). Intakes of total carbohydrates, refined grain starch, wholegrain starch, and total sugars were not associated with CVD outcomes. AMI and ischaemic stroke had similar but stronger directions of association with free sugars compared with IHD and total stroke, respectively, whereas no significant associations were found for haemorrhagic stroke (Additional file 1 Table S9). We found

no evidence of non-linear associations (FDR-adjusted *P*-values all <0.05). Minimally adjusted models and models with adjustment for key cardiometabolic risk factors are shown in Additional file 1 (Tables S10-S12). In the multivariable model (without adjustment for BMI), the association of free sugars with IHD was attenuated and became non-significant following further adjustment for triglycerides or HDL cholesterol (measured by clinical chemistry), while adjustment for cardiometabolic risk factors did not substantially attenuate the associations of free sugars with total stroke.

Analyses of dietary substitution

Modelled isoenergetic replacement of 5% of energy from refined grain starch with wholegrain starch was associated with lower risks of total CVD (0.94; 0.91–0.98; *P*-trend=0.003) and IHD (0.94; 0.90–0.98; *P*-trend=0.006) (Table 3). Replacement of 5% of energy from free sugars with non-free sugars was associated with lower risks of total CVD (0.95; 0.92–0.98; *P*-trend=0.001) and total stroke (0.91; 0.86–0.97; *P*-trend=0.005).

Sensitivity and subgroup analyses

Our findings remained similar after restricting to participants with ≥ three 24-h dietary assessments and ≥ 2 years of follow-up, as well as in sensitivity analyses using absolute intakes of refined grain foods and wholegrain




Fig. 2 Hazard ratios (95% confidence intervals) for the associations between types and sources of carbohydrates and total CVD (A), IHD (B), and total stroke (C) risk in 110,497 UK Biobank participants. Models were stratified by age at recruitment and sex, and adjusted for recruitment region, ethnicity, Townsend deprivation index, education, alcohol intake, smoking status, physical activity, menopausal status, BMI, SBP, SFA intake, and daily energy intake. Models were also adjusted for fruit and vegetable intake, excepting for models with total sugars, non-free sugars, and fibre as the exposure. Full details regarding each covariate are provided in the statistical analysis section in the main text. *P*-trend values using continuous intakes with asterisks indicating statistical significance after using false discovery rate to correct for multiple testing. *P*-trend values ≥0.1 are displayed to two decimal places and *P*-trend values <0.1 are displayed to three decimal places. Abbreviations: BMI body mass index, CI confidence interval, CVD cardiovascular disease, g/d grams per day, IHD ischaemic heart disease, SBP systolic blood pressure, SFA saturated fatty acid

Table 2 Hazard ratios (95% confidence intervals) for the associations between types and sources of carbohydrates by quartiles and total CVD, IHD, and total stroke risk in 110,497 UK Biobank participants

Carbohydrate intakes	Hazard ratios (95% CI)			
	Q1	Q2	Q3	Q4
<i>Total CVD</i>				
Total carbohydrates				
Cases, <i>n</i> (%)	1049	1076	1039	1024
HR (95% CI)	Ref	1.07 (0.98–1.17)	1.06 (0.97–1.17)	1.05 (0.95–1.16)
Refined grain starch				
Cases, <i>n</i> (%)	1104	1110	1021	953
HR (95% CI)	Ref	1.05 (0.96–1.14)	1.00 (0.92–1.10)	0.99 (0.90–1.08)
Wholegrain starch				
Cases, <i>n</i> (%)	1050	1061	1028	1049
HR (95% CI)	Ref	1.03 (0.95–1.13)	1.00 (0.91–1.09)	0.99 (0.91–1.09)
Total sugars				
Cases, <i>n</i> (%)	1034	1004	1072	1078
HR (95% CI)	Ref	0.98 (0.89–1.07)	1.04 (0.95–1.14)	1.07 (0.97–1.17)
Free sugars				
Cases, <i>n</i> (%)	941	1012	1020	1215
HR (95% CI)	Ref	1.04 (0.95–1.13)	1.00 (0.91–1.09)	1.13 (1.03–1.23)
Non-free sugars				
Cases, <i>n</i> (%)	1152	1050	1003	983
HR (95% CI)	Ref	0.95 (0.87–1.04)	0.95 (0.87–1.04)	0.96 (0.87–1.06)
Fibre				
Cases, <i>n</i> (%)	1023	1043	1005	1117
HR (95% CI)	Ref	0.99 (0.91–1.09)	0.92 (0.84–1.02)	0.94 (0.85–1.05)
<i>IHD</i>				
Total carbohydrates				
Cases, <i>n</i> (%)	773	812	788	765
HR (95% CI)	Ref	1.10 (0.99–1.21)	1.11 (0.99–1.23)	1.08 (0.96–1.22)
Refined grain starch				
Cases, <i>n</i> (%)	815	814	784	725
HR (95% CI)	Ref	1.03 (0.93–1.14)	1.02 (0.93–1.13)	0.98 (0.88–1.09)
Wholegrain starch				
Cases, <i>n</i> (%)	787	794	753	804
HR (95% CI)	Ref	1.04 (0.94–1.15)	0.99 (0.90–1.10)	1.03 (0.93–1.15)
Total sugars				
Cases, <i>n</i> (%)	774	754	828	782
HR (95% CI)	Ref	0.99 (0.89–1.10)	1.10 (0.99–1.21)	1.07 (0.96–1.19)
Free sugars				
Cases, <i>n</i> (%)	707	749	778	904
HR (95% CI)	Ref	1.01 (0.91–1.12)	0.99 (0.89–1.10)	1.07 (0.97–1.19)
Non-free sugars				
Cases, <i>n</i> (%)	882	791	746	719
HR (95% CI)	Ref	0.96 (0.87–1.06)	0.97 (0.87–1.08)	1.00 (0.90–1.12)
Fibre				
Cases, <i>n</i> (%)	759	793	752	834
HR (95% CI)	Ref	1.02 (0.92–1.13)	0.93 (0.84–1.04)	0.94 (0.83–1.06)
<i>Total stroke</i>				
Total carbohydrates				
Cases, <i>n</i> (%)	294	285	268	277

Table 2 (continued)

Carbohydrate intakes	Hazard ratios (95% CI)			
	Q1	Q2	Q3	Q4
HR (95% CI)	Ref	1.00 (0.85–1.19)	0.95 (0.80–1.14)	0.97 (0.79–1.18)
Refined grain starch				
Cases, n (%)	304	313	260	247
HR (95% CI)	Ref	1.10 (0.94–1.29)	0.99 (0.83–1.17)	1.03 (0.86–1.22)
Wholegrain starch				
Cases, n (%)	286	284	292	262
HR (95% CI)	Ref	0.99 (0.84–1.17)	1.00 (0.84–1.18)	0.88 (0.74–1.05)
Total sugars				
Cases, n (%)	275	270	264	315
HR (95% CI)	Ref	0.96 (0.81–1.13)	0.91 (0.76–1.08)	1.05 (0.88–1.25)
Free sugars				
Cases, n (%)	247	283	257	337
HR (95% CI)	Ref	1.15 (0.97–1.36)	1.02 (0.85–1.22)	1.33 (1.12–1.58)
Non-free sugars				
Cases, n (%)	293	277	274	280
HR (95% CI)	Ref	0.91 (0.77–1.07)	0.87 (0.73–1.04)	0.84 (0.69–1.01)
Fibre				
Cases, n (%)	279	274	269	302
HR (95% CI)	Ref	0.94 (0.79–1.12)	0.89 (0.74–1.07)	0.94 (0.77–1.15)

Models stratified by age at recruitment and sex, and adjusted for recruitment region, ethnicity, Townsend deprivation index, education, alcohol intake, smoking status, physical activity, menopausal status, BMI, SBP, SFA intake, and daily energy intake. Models were also adjusted for fruit and vegetable intake, excepting for models with total sugars, non-free sugars, and fibre as the exposure. Full details for each covariate are provided in the statistical analysis section in the main text

Abbreviations: BMI body mass index, CI confidence interval, CVD cardiovascular disease, HR hazard ratio, Q quartile, Ref reference, SBP systolic blood pressure, SFA saturated fatty acid

Table 3 Hazard ratios (95% confidence intervals) for the associations between each isoenergetic replacement of 5% of energy from free sugars or refined grains with other carbohydrates and incidence of total CVD, IHD, and total stroke in 110,497 UK Biobank participants

Isoenergetic substitution model ^a	Total CVD (4188 cases)		IHD (3138 cases)		Total stroke (1124 cases)	
	HR (95% CI)	P-trend ^b	HR (95%CI)	P-trend ^b	HR (95%CI)	P-trend ^b
Substituting 5% of energy from refined grain starch for 5% of energy from wholegrain starch	0.94 (0.91–0.98)	0.003*	0.94 (0.90–0.98)	0.006*	0.94 (0.87–1.01)	0.11
Substituting 5% of energy from free sugars for 5% of energy from non-free sugars	0.95 (0.92–0.98)	0.001*	0.96 (0.92–0.99)	0.023	0.91 (0.86–0.97)	0.005*

* P-trend statistically significant after using false discovery rate to correct for multiple testing

^a Isoenergetic substitution models included the same adjustments as per Fig. 2 excluding intake of SFA intake and fruit and vegetable intake, and were further adjusted for energy from all macronutrients excluding the carbohydrate type or source being replaced. Full details for each covariate are provided in the statistical analysis section in the main text

^b P-trend using continuous intakes. P-trend values ≥0.1 are displayed to two decimal places and P-trend values <0.1 are displayed to three decimal places

Abbreviations: CI confidence interval, CVD cardiovascular disease, HR hazard ration, IHD ischaemic heart disease, SFA saturated fatty acid

foods as the exposure (Additional file 1 Tables S13–S15). No significant heterogeneity by sex, BMI, and smoking subgroups for associations between carbohydrate intakes and cardiovascular outcomes was observed (Additional file 1 Tables S16–S18).

Associations of carbohydrate intakes with triglycerides in lipoprotein subclasses

Free sugars were most strongly associated with CVD outcomes in our study and were also associated with total triglycerides measured by clinical chemistry in

our previous analyses [9]; therefore, we examined the associations of free sugars with plasma triglycerides within lipoprotein subclasses in a subsample of participants with NMR spectroscopy measurements ($n=26,095$). There was a high correlation for log-transformed total triglyceride concentrations measured by clinical chemistry and NMR spectroscopy ($r=0.94$). Free sugar intake was positively associated with total triglycerides (percentage difference in triglyceride concentration per 5% of energy intake 3.04; 95% CI 2.53–3.55) and triglycerides within all lipoprotein subclasses; the strongest associations were observed for triglycerides in chylomicrons and extremely large very low-density lipoprotein (VLDL; 10.12; 7.51–12.79) and very large VLDL (7.36; 6.11–8.62) (Table 4, see Additional file 1 Table S19 for minimally adjusted analyses). In sensitivity analyses restricted to participants fasting for ≥ 4 h at blood collection ($n=11,076$) and participants with all triglyceride measurements above the LOQ ($n=21,865$) the directions of association remained similar (Additional file 1 Tables S20–S21).

Discussion

In this large UK study, higher free sugar intake was significantly positively associated with risks of incident total CVD, IHD, and total stroke, while higher fibre intake was inversely associated with total CVD. Modelled replacement of refined grain starch with wholegrain starch was associated with lower risks of total CVD and IHD, and replacement of free sugars with non-free sugars was associated with lower risks of total CVD and total stroke. Moreover, higher free sugar intake was associated with higher concentrations of total triglycerides and triglycerides within all lipoprotein subclasses.

Few large observational studies of dietary carbohydrates and CVD risk have examined the types and sources of total carbohydrates in detail [2]. This study found no association between total carbohydrate intake and risk of CVD, which is consistent with most previous prospective studies [2, 3]. The findings of our study suggest that specific types of carbohydrate, particularly different sugars, may have diverging associations with CVD risk; we found that intake of free sugars was positively associated

Table 4 Associations for each 5% of energy from free sugars and concentrations of total triglycerides and triglycerides in lipoprotein subclasses in 26,095 UK Biobank participants

Triglycerides	Geometric mean (95% CI), mmol/L	Percentage difference mean concentrations (95% CI)
Total triglycerides	1.142 (1.136, 1.148)	3.04 (2.53, 3.55)
Triglycerides in VLDL	0.760 (0.755, 0.765)	3.77 (3.14, 4.40)
Triglycerides in chylomicrons and extremely large VLDL	0.058 (0.057, 0.060)	10.12 (7.51, 12.79)
Triglycerides in very large VLDL	0.073 (0.073, 0.074)	7.36 (6.11, 8.62)
Triglycerides in large VLDL	0.135 (0.134, 0.136)	3.94 (3.21, 4.68)
Triglycerides in medium VLDL	0.241 (0.240, 0.243)	2.61 (2.08, 3.14)
Triglycerides in small VLDL	0.141 (0.140, 0.142)	2.50 (2.03, 2.97)
Triglycerides in very small VLDL	0.064 (0.064, 0.064)	1.86 (1.49, 2.24)
Triglycerides in LDL	0.095 (0.094, 0.095)	1.32 (1.02, 1.63)
Triglycerides in LDL	0.136 (0.136, 0.137)	1.45 (1.12, 1.77)
Triglycerides in large LDL	0.092 (0.092, 0.092)	1.27 (0.97, 1.58)
Triglycerides in medium LDL	0.030 (0.030, 0.030)	1.65 (1.29, 2.00)
Triglycerides in small LDL	0.013 (0.013, 0.013)	2.14 (1.74, 2.55)
Triglycerides in HDL	0.134 (0.133, 0.134)	2.21 (1.80, 2.62)
Triglycerides in large HDL	0.028 (0.028, 0.028)	1.52 (1.01, 2.03)
Triglycerides in medium HDL	0.049 (0.049, 0.050)	2.44 (1.98, 2.89)
Triglycerides in small HDL	0.048 (0.047, 0.048)	2.70 (2.28, 3.12)

Multivariable linear regression models with free sugar intake as an independent variable and triglyceride measurements as dependent variables were adjusted for age at recruitment, sex, recruitment region, ethnicity, Townsend deprivation index, education, alcohol intake, smoking status, physical activity, menopausal status, SBP, BMI, fruit and vegetable intake, SFA intake, daily energy intake, and fasting status. Full details for each covariate are provided in the statistical analysis section in the main text. Results are expressed as the percentage difference (95% CI) in triglyceride concentrations per 5% higher energy intake from free sugars and were calculated as follows: $(e^{\beta} - 1) * 100$

P-trend values calculated using continuous intakes were all significant after using false discovery rate to correct for multiple testing. *P*-trend values ≥ 0.1 are displayed to two decimal places and *P*-trend values < 0.1 are displayed to three decimal places

Abbreviations: BMI body mass index, CI confidence intervals, CVD cardiovascular disease, HDL high-density lipoprotein, LDL intermediate-density lipoprotein, LDL low-density lipoprotein cholesterol, SBP systolic blood pressure, SFA saturated fatty acid, VLDL very low-density lipoprotein cholesterol

with total CVD and all CVD subtypes except for haemorrhagic stroke, while intake of non-free sugars was not associated with CVD outcomes. To the best of our knowledge, no prior study has examined the associations of free sugars, based on the definition revised in 2015 by the World Health Organization [6] and the UK Scientific Advisory Committee on Nutrition [2], with CVD risks, as most previous studies have only looked at added sugars or sucrose as a proxy for free sugars [16, 17]. In 2016, a meta-analysis of observational studies found that added sugars, all of which are free sugars but exclude sugars in juiced or pureed fruit and vegetables, were not associated with total CVD mortality; however, data were not available to assess the associations of added sugars and incident total CVD, and CVD subtypes were not examined separately [16]. SSBs are rich in free sugars, and a recent meta-analysis of 7 prospective cohort studies found that each one serving/d of SSBs was associated with significantly higher risks of total CVD (RR 1.08; 95% CI 1.02–1.14) and IHD (1.15; 1.09–1.22) but not total stroke (1.05; 0.95–1.16), although in subgroup analyses SSB intake was significantly associated with ischaemic stroke risk among women (1.33; 1.07–1.66) [15].

Free sugars were most strongly associated with total stroke risk in our whole cohort analyses; however, a majority of participants were women (58%), and although we observed no significant heterogeneity by sex in our subgroup analyses, we found that risk estimates for free sugars and total stroke tended to be larger for women (HR 1.15; 95% CI 1.05–1.26) compared with men (1.06; 95% CI 0.98–1.16). Moreover, SSBs were an important source of free sugar intake in our sample (11.4% of free sugar intake), which may partly account for our findings, although fruit juice, which has previously been found to have neutral or inverse associations with CVD risk, was a larger source of free sugars in this sample (15.9% of free sugar intake) [41]. It is possible that specific food sources of free sugars have diverging associations with CVD risk, but we were unable to examine major sources of free sugars separately due to the high number of participants who did not report consuming SSBs and fruit juice across completed 24-h dietary assessments. Further, we found that statistically modelled replacement of free sugars with non-free sugars was associated with lower risks of total CVD and total stroke, which has not been demonstrated previously. Prior observational evidence suggests that fruit, vegetables, and dairy products, which are major dietary sources of non-free sugars, are inversely associated with CVD risk [42–44], and that this may partly explain the observed beneficial association with modelled substitution of free sugars for non-free sugars, although we observed no significant inverse associations of non-free sugars in our main analyses.

Previous RCTs have demonstrated that reducing free sugar intake reduces total energy intake [2, 8], which may relate to lower body weight, and adiposity is an established risk factor for IHD and stroke [45]. However, adding BMI to our main multivariable models did not attenuate the observed associations between free sugars and incident CVD. There is limited evidence for the association of free sugars with other cardiometabolic risk factors (i.e. elevated blood pressure, and fasting glucose) [8, 46–48], although we observed that associations of free sugars with total CVD and IHD attenuated most after adjustment for serum triglycerides and HDL cholesterol. Our recent study in the UK Biobank found that each 5% higher energy from free sugars was associated with higher triglycerides (+0.15 mmol/l) and lower HDL cholesterol (−0.07 mmol/L) [9]. Moreover, MR studies support a causal effect of triglycerides on IHD risk [49, 50], but have strongly suggested that HDL cholesterol is not causal [49, 51], and it is possible that associations of triglycerides vary by the type of transporting lipoprotein particle [10]. For each 5% higher energy from free sugars we observed modestly higher concentrations of log-transformed total triglycerides (+3.04%), with the highest concentrations observed for triglycerides within larger VLDL particles (+10.12%). While many observational and genetic studies have suggested that VLDL particles are associated with higher risk of ischaemic heart disease [52–55], a recent study found that a large proportion of myocardial infarction risk related to apolipoprotein B-containing particles was explained by VLDL cholesterol, but not VLDL triglycerides [56]. Thus, it is possible that the observed associations between free sugars and triglycerides in apolipoprotein B-containing particles are related to the cholesterol rather than triglyceride content of these particles. Moreover, evidence from observational and genetic studies does not support a causal association of triglycerides with total stroke risk [49, 50, 57]. This suggests that triglycerides may not explain the higher risks of total stroke observed with higher free sugar intakes in our study. Our findings for free sugars and stroke attenuated minimally after adjustment for other cardiometabolic risk factors (e.g. adiposity and elevated blood pressure) [58]; further research is warranted to examine the plausible mechanisms for this association.

Starch from refined grains and wholegrains were not associated with CVD incidence in our study [59–62]. In contrast, previous studies have found that wholegrain food intake is associated with lower risks of IHD and stroke [18, 63], and while overall evidence is limited for refined grain foods, the Prospective Urban and Rural Epidemiology study including 137,000 individuals from five low- and middle-income countries recently reported

that intakes of ≥ 350 g/d of refined grain foods were positively associated with major CVD events [19]. However, we observed that modelled replacement of refined grain starch with wholegrain starch was associated with lower risks of IHD and total CVD. Meta-analyses of RCTs show that substitution of refined grain foods with wholegrain foods lowers total cholesterol, LDL cholesterol, and HbA1c [64], which may explain the lower risks of IHD and CVD observed for our modelled substitution analyses [49, 50, 65]. Our study separates the starch in refined grain foods from other macronutrients, such as SFAs and free sugars, which have been found to have harmful associations with CVD risk, to better approximate the amount of wholegrain and refined grain consumed [27, 66]. It is possible that the higher dietary fibre content or potentially the mineral, vitamin, and phytochemical content of wholegrains may still account for some of the beneficial associations observed in this modelled substitution [63].

Lastly, our study confirms the established inverse association between dietary fibre and risk of total CVD [18, 67]. Specifically, we found a 4% lower risk of total CVD for each 5 g/d higher fibre intake, compared to a 9% lower risk of total CVD for each 7 g/d higher fibre intake reported in a recent meta-analysis [18]. However, associations of fibre intake with total CVD in analyses by fourths of intakes attenuated and became non-significant after adjustment for BMI, as well as after adjustment for LDL cholesterol or ApoB measured by clinical chemistry. Meta-analyses of RCTs have found that higher fibre intake lowers body weight and serum LDL cholesterol concentrations [18, 68], which may partly explain the beneficial associations observed for each 5 g/d higher fibre intake in this study. Moreover, highest consumers of fibre in our study (≥ 21 g/d) had lower mean BMI, waist circumference, and LDL cholesterol.

Strengths and limitations

Strengths of this study include the large cohort size, prospective study design, and detailed dietary information that allowed the determination of several carbohydrate types and sources. Further, triglycerides measured by NMR spectroscopy at baseline were available for a large subsample of participants ($n=26,095$, 24%), allowing us to examine the novel associations of free sugars and triglycerides in different lipoprotein subclasses.

There are some limitations of the present study to consider. All self-reported dietary assessment techniques are prone to error; however, we have used the average of at least two (maximum 5) 24-h dietary assessments per participant and removed implausible intakes. In a recent validation study, correlations between the mean

of two Oxford WebQ's and estimated true intakes of total sugar and total energy were 0.40 and 0.38, respectively, and improved with further administrations [23]. Moreover, our findings remained similar in sensitivity analyses restricted to participants with \geq three 24-h dietary assessments, and estimates for total carbohydrates, total sugars, free sugars, and fibre intakes were comparable with those observed for adults aged 19–64 years in the National Diet and Nutrition Survey (2017–2018) [69]. We were unable to account for changes in dietary intakes during the study follow-up period, which potentially increased random error and could have biased associations towards the null. Reverse causality is possible, although we removed individuals with CVD and diabetes at baseline and the findings of our study remained similar after excluding the first 2 years of follow-up. The nature of our analyses of free sugars and triglyceride measurements did not allow us to consider temporality because blood samples were taken several months prior to the completion of most 24-h dietary assessments. Further, our interpretation of sensitivity analyses for stroke was limited by the smaller number of cases after further exclusions. Residual confounding may have influenced our findings, given the moderate to large reductions in χ^2 values after adjustment for some cardiometabolic risk factors in our models for total CVD and IHD, and, as with all observational studies, causality cannot be inferred. Lastly, participants recruited to the UK Biobank are mostly of white European ancestry and are typically healthier than the overall population [70], so our findings may not be generalisable to other populations.

Conclusions

In summary, we found that associations between carbohydrate intakes and CVD may depend on the type and source of carbohydrate consumed, particularly for sugars. Free sugar intake was associated with higher risks of total CVD and CVD subtypes, particularly total stroke, which supports the global dietary recommendation to consume less than 5% of total energy from free sugars [6]. Free sugar intake was positively associated with triglycerides within all lipoprotein subclasses, which may partly explain the observed higher risk of IHD, while mechanisms for higher total stroke risk remain unclear. Higher fibre intake was associated with lower risks of total CVD, and replacement of refined grain starch and free sugars with wholegrain starch and non-free sugars, respectively, may be protective for CVD. Our findings support the importance of the type and source of carbohydrate consumed for cardiovascular health.

Abbreviations

AMI	Acute myocardial infarction
Apo	Apolipoprotein
BMI	Body mass index
CI	Confidence interval
CVD	Cardiovascular disease
g/d	Grams per day
HbA1c	Glycated haemoglobin
HDL	High-density lipoprotein
HR	Hazard ratio
ICD	International Classification of Diseases
IDL	Intermediate-density lipoprotein
IHD	Ischaemic heart disease
LDL	Low-density lipoprotein
LOQ	Limit of quantification
LR	Likelihood ratio
MET	Metabolic equivalent of task
NHS	National Health Service
NMR	Nuclear magnetic resonance
NSP	Non-starch polysaccharide
OPCS	Classification of Interventions and Procedures
Q	Quartile
RCT	Randomised controlled trial
ref	Reference
SBP	Systolic blood pressure
SD	Standard deviation
SFA	Saturated fatty acid
SSB	Sugar-sweetened beverage
VLDL	Very low-density lipoprotein

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12916-022-02712-7>.

Additional file 1: Supplemental methods. Assessment of covariates; Measurement and analyses of triglycerides in lipoprotein classes. **Table S1.** Description of types and sources of dietary carbohydrates. **Table S2.** Outcome definitions for incident CVD and exclusion criteria for prevalent CVD and diabetes. **Table S3.** Triglyceride concentrations measured by NMR spectroscopy flagged as being below the limit of quantification in 26,095 UK Biobank participants. **Table S4.** Baseline characteristics across quartiles of total carbohydrate intake in 110,497 UK Biobank participants. **Table S5.** Baseline characteristics across quartiles of free sugar intake in 110,497 UK Biobank participants. **Table S6.** Baseline characteristics across quartiles of fibre intake in 110,497 UK Biobank participants. **Table S7.** Carbohydrate intakes in grams per day and percentage of energy intake by quartiles of carbohydrate intakes. **Table S8.** Types and sources of carbohydrates in grams per day and percentage of energy intake by quartiles of total carbohydrate intake. **Table S9.** Hazard ratios (95% confidence intervals) for the associations between types and sources of carbohydrates and acute myocardial infarction, ischaemic stroke, and haemorrhagic stroke risk in 110,497 UK Biobank participants. **Table S10.** Hazard ratios (95% confidence intervals) for the associations between carbohydrate intakes and incidence of total CVD in 110,497 UK Biobank participants with adjustment for key cardiometabolic risk factors. **Table S11.** Hazard ratios (95% confidence intervals) for the associations between carbohydrate intakes and incidence of IHD in 110,497 UK Biobank participants with adjustment for key cardiometabolic risk factors. **Table S12.** Hazard ratios (95% confidence intervals) for the associations between carbohydrate intakes and incidence of total stroke in 110,497 UK Biobank participants with adjustment for key cardiometabolic risk factors. **Table S13.** Hazard ratios (95% confidence intervals) for the associations between carbohydrate intakes and total CVD, IHD and total stroke risk in sensitivity analyses restricting to participants with \geq three 24-h dietary assessments (n=67,218). **Table S14.** Hazard ratios (95% confidence intervals) for the associations between carbohydrate intakes and total CVD, IHD and total stroke risk in sensitivity analyses restricting to participants with \geq two years of follow-up (n=109,682). **Table S15.** Hazard ratios (95% confidence intervals) for the associations between

intake of refined grain foods and wholegrain foods in grams and total CVD, IHD and total stroke risk (n=110,497). **Table S16.** Hazard ratios (95% confidence intervals) for the associations between types of carbohydrate and total CVD, IHD and total stroke risk in 110,497 UK Biobank participants by sex subgroups. **Table S17.** Hazard ratios (95% confidence intervals) for the associations between types of carbohydrate and total CVD, IHD and total stroke risk in 110,497 UK Biobank participants by BMI subgroups. **Table S18.** Hazard ratios (95% confidence intervals) for the associations between types of carbohydrate and total CVD, IHD and total stroke risk in 110,497 UK Biobank participants by smoking status subgroups. **Table S19.** Associations between each 5% of energy from free sugars and concentrations of total triglycerides and triglycerides in lipoprotein subclasses in minimally adjusted linear regression models in 26,095 UK Biobank participants. **Table S20.** Associations between each 5% of energy from free sugars and concentrations of total triglycerides and triglycerides in lipoprotein subclasses in sensitivity analyses restricting to participants fasting for \geq 4 h prior to serum collection (n=11,076). **Table S21.** Associations between each 5% of energy from free sugars and concentrations of total triglycerides and triglycerides in lipoprotein subclasses in sensitivity analyses restricting to participants above the limit of quantification (n=21,865). **Fig. S1** Dietary assessments in subsample of 110,497 UK Biobank participants included in our main analyses. **Fig. S2** Top five food contributors to total carbohydrates and types of carbohydrates in 110,497 UK Biobank participants.

Acknowledgements

This research has been conducted using the UK Biobank Resource under application number 24494. We thank all participants, researchers, and support staff who make the study possible.

Authors' contributions

The study was conceived and designed by RKK and APC with input from all study authors. The data were analysed by RKK, TYNT, CZW, AR, CP, AS, KP, JLC, TJK, and APC provided input on data analysis and interpretation of results. The first draft of the manuscript was prepared by RKK and APC with input from TJK and TYNT. All authors revised the manuscript critically for important intellectual content and gave final approval of the version to be submitted. RKK is the guarantor.

Funding

RKK is supported by the Clarendon Scholarship from the University of Oxford. TYNT is supported by the Nuffield Department of Population Health Intermediate Fellowship and the UK Medical Research Council (grant number MR/M012190/1). CZW is supported by the Nuffield Department of Population Health Doctor of Philosophy student scholarship. AR is supported by the National Heart Foundation of New Zealand. CP is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration (ARC). KP and TJK are supported by the Wellcome Trust, Our Planet Our Health (Livestock, Environment, and People – LEAP) grant number (grant number 205212/Z/16/Z). KP is supported by Cancer Research UK (grant numbers C570/A16491, A29186). JLC is supported by core grants to CTSU (Clinical Trial Service Unit) from the Medical Research Council (grant number CTSU A310) (Swindon, UK) and the British Heart Foundation (grant number CH/1996001/9454), and by the NIHR Oxford Biomedical Research Centre. TJK and JS are supported by Cancer Research UK (grant number C8221/A19170). APC is supported by a Cancer Research UK Population Research Fellowship (grant number C60192/A28516) and by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (grant number 2019/1953).

Availability of data and materials

Bona fide researchers can apply to use the UK Biobank dataset by registering and applying at <http://ukbiobank.ac.uk/register-apply/>.

Declarations**Ethics approval and consent to participate**

The UK Biobank was approved by the NHS North West Multicentre Research Ethics Committee (approval letter dated 29th of June 2021, reference 21/NW/0157), and all participants provided informed consent to participate and

be followed through linkage to their health records. Further details regarding the study protocol and data access for researchers have been published elsewhere (<https://www.ukbiobank.ac.uk/media/gnkeyh2q/study-rationale.pdf>).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UK.

²Department of Medicine, University of Otago, Dunedin 9016, New Zealand.

³Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX3 7LF, UK. ⁴Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. ⁵Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK.

Received: 8 September 2022 Accepted: 14 December 2022

Published online: 14 February 2023

References

- GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. *Lancet*. 2020;396:1223–49. [https://doi.org/10.1016/s0140-6736\(20\)30752-2](https://doi.org/10.1016/s0140-6736(20)30752-2).
- Scientific Advisory Committee on Nutrition. Carbohydrates and health. London: Public Health England; 2015. <https://www.gov.uk/government/publications/sacn-carbohydrates-and-health-report>. Accessed 11 Jun 2022
- Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. *Lancet*. 2017;390:2050–62. [https://doi.org/10.1016/s0140-6736\(17\)32252-3](https://doi.org/10.1016/s0140-6736(17)32252-3).
- AlEsa HB, Cohen R, Malik VS, Adebamowo SN, Rimm EB, Manson JE, et al. Carbohydrate quality and quantity and risk of coronary heart disease among US women and men. *Am J Clin Nutr*. 2018;107:257–67. <https://doi.org/10.1093/ajcn/nqx060>.
- Swan GE, Powell NA, Knowles BL, Bush MT, Levy LB. A definition of free sugars for the UK. *Public Health Nutr*. 2018;21:1636–8. <https://doi.org/10.1017/s136898001800085x>.
- World Health Organization. Guideline: sugars intake for adults and children. Geneva: WHO; 2015. <https://www.who.int/publications/i/item/9789241549028>. Accessed 12 July 2022.
- US Department of Agriculture and US Department of Health and Human Services. Dietary guidelines for Americans 2020–2025. Washington: US Department of Agriculture and US Department of Health and Human Services; 2020. <https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materials>. Accessed 17 Apr 2022.
- Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. *BMJ*. 2012;346:e7492. <https://doi.org/10.1136/bmj.e7492>.
- Kelly RK, Watling CZ, Tong TYN, Piernas C, Carter JL, Papier K, et al. Associations between macronutrients from different dietary sources and serum lipids in 24 639 UK biobank study participants. *Arterioscler Thromb Vasc Biol*. 2021;41:2190–200. <https://doi.org/10.1161/atvbaha.120.315628>.
- Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. *J Am Coll Cardiol*. 2018;71:620–32. <https://doi.org/10.1016/j.jacc.2017.12.006>.
- Ference BA. Causal effect of lipids and lipoproteins on atherosclerosis: lessons from genomic studies. *Cardiol Clin*. 2018;36:203–11. <https://doi.org/10.1016/j.ccl.2017.12.001>.
- Xi B, Huang Y, Reilly KH, Li S, Zheng R, Barrio-Lopez MT, et al. Sugar-sweetened beverages and risk of hypertension and CVD: a dose-response meta-analysis. *Br J Nutr*. 2015;113:709–17. <https://doi.org/10.1017/s0007114514004383>.
- Huang C, Huang J, Tian Y, Yang X, Gu D. Sugar sweetened beverages consumption and risk of coronary heart disease: a meta-analysis of prospective studies. *Atherosclerosis*. 2014;234:11–6. <https://doi.org/10.1016/j.atherosclerosis.2014.01.037>.
- Narain A, Kwok CS, Mamas MA. Soft drinks and sweetened beverages and the risk of cardiovascular disease and mortality: a systematic review and meta-analysis. *Int J Clin Pract*. 2016;70:791–805. <https://doi.org/10.1111/ijcp.12841>.
- Yin J, Zhu Y, Malik V, Li X, Peng X, Zhang FF, et al. Intake of sugar-sweetened and low-calorie sweetened beverages and risk of cardiovascular disease: a meta-analysis and systematic review. *Adv Nutr*. 2021;12:89–101. <https://doi.org/10.1093/advances/nmaa084>.
- Khan TA, Tayyiba M, Agarwal A, Mejia SB, de Souza RJ, Wolever TMS, et al. Relation of total sugars, sucrose, fructose, and added sugars with the risk of cardiovascular disease: a systematic review and dose-response meta-analysis of prospective cohort studies. *Mayo Clin Proc*. 2019;94:2399–414. <https://doi.org/10.1016/j.mayocp.2019.05.034>.
- Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Knutson HK, et al. Tolerable upper intake level for dietary sugars. *EFSA J*. 2022;20:e07074. <https://doi.org/10.2903/j.efsa.2022.7074>.
- Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet*. 2019;393:434–45. [https://doi.org/10.1016/s0140-6736\(18\)31809-9](https://doi.org/10.1016/s0140-6736(18)31809-9).
- Swaminathan S, Dehghan M, Raj JM, Thomas T, Rangarajan S, Jenkins D, et al. Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in prospective urban and rural epidemiology study: prospective cohort study. *BMJ*. 2021;372:m4948. <https://doi.org/10.1136/bmj.m4948>.
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12:e1001779. <https://doi.org/10.1371/journal.pmed.1001779>.
- UK Biobank. UK biobank: protocol for a large-scale prospective epidemiological resource. Oxford: UK Biobank; 2007. <https://www.ukbiobank.ac.uk/media/gnkeyh2q/study-rationale.pdf>. Accessed 27 Oct 2022.
- Liu B, Young H, Crowe FL, Benson VS, Spencer EA, Key TJ, et al. Development and evaluation of the Oxford WebQ, a low-cost, web-based method for assessment of previous 24 h dietary intakes in large-scale prospective studies. *Public Health Nutr*. 2011;14:1998–2005. <https://doi.org/10.1017/s1368980011000942>.
- Greenwood DC, Hardie LJ, Frost GS, Alwan NA, Bradbury KE, Carter M, et al. Validation of the Oxford WebQ online 24-hour dietary questionnaire using biomarkers. *Am J Epidemiol*. 2019;188:1858–67. <https://doi.org/10.1093/aje/kwz165>.
- Perez-Cornago A, Pollard Z, Young H, van Uden M, Andrews C, Piernas C, et al. Description of the updated nutrition calculation of the Oxford WebQ questionnaire and comparison with the previous version among 207,144 participants in UK biobank. *Eur J Nutr*. 2021;60:4019–30. <https://doi.org/10.1007/s00394-021-02558-4>.
- Englyst HN, Cummings JH. Improved method for measurement of dietary fiber as non-starch polysaccharides in plant foods. *J Assoc Off Anal Chem*. 1988;71:808–14. <https://doi.org/10.1093/JAOAC/71.4.808>.
- Piernas C, Perez-Cornago A, Gao M, Young H, Pollard Z, Mulligan A, et al. Describing a new food group classification system for UK biobank: analysis of food groups and sources of macro- and micronutrients in 208,200 participants. *Eur J Nutr*. 2021;60:2879–90. <https://doi.org/10.1007/s00394-021-02535-x>.
- Shewry PR, Hey SJ. The contribution of wheat to human diet and health. *Food Energy Secur*. 2015;4:178–202. <https://doi.org/10.1002/fes3.64>.
- Carter JL, Lewington S, Piernas C, Bradbury K, Key TJ, Jebb SA, et al. Reproducibility of dietary intakes of macronutrients, specific food groups, and dietary patterns in 211 050 adults in the UK biobank study. *J Nutr Sci*. 2019;8:e34. <https://doi.org/10.1017/jns.2019.31>.
- Rubbo B, Fitzpatrick NK, Denaxas S, Daskalopoulou M, Yu N, Patel RS, et al. Use of electronic health records to ascertain, validate and phenotype acute myocardial infarction: a systematic review and recommendations. *Int J Cardiol*. 2015;187:705–11. <https://doi.org/10.1016/j.ijcard.2015.03.075>.

30. Woodfield R, Grant I, Sudlow CL. Accuracy of electronic health record data for identifying stroke cases in large-scale epidemiological studies: a systematic review from the UK biobank stroke outcomes group. *PLoS One*. 2015;10:e0140533. <https://doi.org/10.1371/journal.pone.0140533>.
31. Woodfield R, Sudlow CL. Accuracy of patient self-report of stroke: a systematic review from the UK biobank stroke outcomes group. *PLoS One*. 2015;10:e0137538. <https://doi.org/10.1371/journal.pone.0137538>.
32. Kivimäki M, Batty GD, Singh-Manoux A, Britton A, Brunner EJ, Shipley MJ. Validity of cardiovascular disease event ascertainment using linkage to UK hospital records. *Epidemiology*. 2017;28:735–9. <https://doi.org/10.1097/ede.0000000000000688>.
33. UK Biobank. Nightingale health metabolic biomarkers: phase 1 release. Oxford: UK Biobank; 2021. https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/nmrm_companion_doc.pdf. Accessed 4 May 2022
34. Joshi R, Wannamethee SG, Engmann J, Gaunt T, Lawlor DA, Price J, et al. Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: a prospective analysis in 11,560 adults. *Eur J Prev Cardiol*. 2020;27:1617–26. <https://doi.org/10.1177/2047487319899621>.
35. Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Gunter MJ, Holmes MV, et al. NMR metabolite profiles in male meat-eaters, fish-eaters, vegetarians and vegans, and comparison with MS metabolite profiles. *Metabolites*. 2021;11:121. <https://doi.org/10.3390/metabo11020121>.
36. Lu W, Su X, Klein MS, Lewis IA, Fiehn O, Rabinowitz JD. Metabolite measurement: pitfalls to avoid and practices to follow. *Annu Rev Biochem*. 2017;86:277–304. <https://doi.org/10.1146/annurev-biochem-061516-044952>.
37. Elliott P, Peakman TC. The UK biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. *Int J Epidemiol*. 2008;37:234–44. <https://doi.org/10.1093/ije/dym276>.
38. Willett W. *Nutritional epidemiology*. 3rd ed. Boston: Oxford University Press; 2012.
39. Floud S, Balkwill A, Canoy D, Reeves GK, Green J, Beral V, et al. Social participation and coronary heart disease risk in a large prospective study of UK women. *Eur J Prev Cardiol*. 2016;23:995–1002. <https://doi.org/10.1177/2047487315607056>.
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. *J R Stat Soc Ser B*. 1995;57:289–300. <https://doi.org/10.1111/j.2517-6161.1995.tb02031.x>.
41. D'Elia L, Dinu M, Sofi F, Volpe M, Strazzullo P. 100% fruit juice intake and cardiovascular risk: a systematic review and meta-analysis of prospective and randomised controlled studies. *Eur J Nutr*. 2021;60:2449–67. <https://doi.org/10.1007/s00394-020-02426-7>.
42. Bechthold A, Boeing H, Schwedhelm C, Hoffmann G, Knüppel S, Iqbal K, et al. Food groups and risk of coronary heart disease, stroke and heart failure: a systematic review and dose-response meta-analysis of prospective studies. *Crit Rev Food Sci Nutr*. 2019;59:1071–90. <https://doi.org/10.1080/10408398.2017.1392288>.
43. Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies. *Int J Epidemiol*. 2017;46:1029–56. <https://doi.org/10.1093/ije/dyw319>.
44. Fontecha J, Calvo MV, Juarez M, Gil A, Martinez-Vizcaino V. Milk and dairy product consumption and cardiovascular diseases: an overview of systematic reviews and meta-analyses. *Adv Nutr*. 2019;10:S164–S89. <https://doi.org/10.1093/advances/nmy099>.
45. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med*. 2017;377:13–27. <https://doi.org/10.1056/NEJMoa1614362>.
46. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. *Am J Clin Nutr*. 2006;84:274–88. <https://doi.org/10.1093/ajcn/84.1.274>.
47. Imamura F, O'Connor R, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. *BMJ*. 2015;351:h3576. <https://doi.org/10.1136/bmj.h3576>.
48. Jayalath VH, de Souza RJ, Ha V, Mirrahimi A, Blanco-Mejia S, Di Buono M, et al. Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts. *Am J Clin Nutr*. 2015;102:914–21. <https://doi.org/10.3945/ajcn.115.107243>.
49. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J*. 2015;36:539–50. <https://doi.org/10.1093/eurheartj/ehv571>.
50. Allara E, Morani G, Carter P, Gkatzionis A, Zuber V, Foley CN, et al. Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled Mendelian randomization investigation. *Circ Genom Precis Med*. 2019;12:e002711. <https://doi.org/10.1161/circgen.119.002711>.
51. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet*. 2012;380:572–80. [https://doi.org/10.1016/s0140-6736\(12\)60312-2](https://doi.org/10.1016/s0140-6736(12)60312-2).
52. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nat Genet*. 2013;45:1345–52. <https://doi.org/10.1038/ng.2795>.
53. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. *JAMA*. 2019;321:364–73. <https://doi.org/10.1001/jama.2018.20045>.
54. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet*. 2014;384:626–35. [https://doi.org/10.1016/s0140-6736\(14\)61177-6](https://doi.org/10.1016/s0140-6736(14)61177-6).
55. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet*. 2010;375:1634–9. [https://doi.org/10.1016/s0140-6736\(10\)60545-4](https://doi.org/10.1016/s0140-6736(10)60545-4).
56. Balling M, Afzal S, Varbo A, Langsted A, Davey Smith G, Nordestgaard BG. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. *J Am Coll Cardiol*. 2020;76:2725–35. <https://doi.org/10.1016/j.jacc.2020.09.610>.
57. Hindy G, Engström G, Larsson SC, Traylor M, Markus HS, Melander O, et al. Role of blood lipids in the development of ischemic stroke and its subtypes: a mendelian randomization study. *Stroke*. 2018;49:820–7. <https://doi.org/10.1161/strokeaha.117.019653>.
58. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. *Lancet Neurol*. 2021;20:795–820. [https://doi.org/10.1016/s1474-4422\(21\)00252-0](https://doi.org/10.1016/s1474-4422(21)00252-0).
59. Fehily AM, Yarnell JW, Sweetnam PM, Elwood PC. Diet and incident ischaemic heart disease: the Caerphilly study. *Br J Nutr*. 1993;69:303–14. <https://doi.org/10.1079/bjn19930035>.
60. Pietinen P, Rimm EB, Korhonen P, Hartman AM, Willett WC, Albanes D, et al. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The alpha-Tocopherol, Beta-carotene cancer prevention study. *Circulation*. 1996;94:2720–7. <https://doi.org/10.1161/01.cir.94.11.2720>.
61. Liu S. Intake of refined carbohydrates and whole grain foods in relation to risk of type 2 diabetes mellitus and coronary heart disease. *J Am Coll Nutr*. 2002;21:298–306. <https://doi.org/10.1080/07315724.2002.10719227>.
62. Beulens JW, de Bruijne LM, Stolk RP, Peeters PH, Bots ML, Grobbee DE, et al. High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. *J Am Coll Cardiol*. 2007;50:14–21. <https://doi.org/10.1016/j.jacc.2007.02.068>.
63. Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, et al. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. *BMJ*. 2016;353:i2716. <https://doi.org/10.1136/bmj.i2716>.
64. Marshall S, Petocz P, Duve E, Abbott K, Cassettari T, Blumfield M, et al. The effect of replacing refined grains with whole grains on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials with GRADE clinical recommendation. *J Acad Nutr Diet*. 2020;120:1859–83.e31. <https://doi.org/10.1016/j.jand.2020.06.021>.
65. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Paré G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. *Eur Heart J*. 2015;36:1454–62. <https://doi.org/10.1093/eurheartj/ehv083>.
66. Hooper L, Martin N, Abdelhamid A, Davey SG. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev*. 2015;CD011737. <https://doi.org/10.1002/14651858.Cd011737>.
67. Perez-Cornago A, Crowe FL, Appleby PN, Bradbury KE, Wood AM, Jakobsen MU, et al. Plant foods, dietary fibre and risk of ischaemic heart disease in the European prospective investigation into cancer and nutrition (EPIC) cohort. *Int J Epidemiol*. 2021;50:212–22. <https://doi.org/10.1093/ije/dyaa155>.

68. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*. 1999;69:30–42. <https://doi.org/10.1093/ajcn/69.1.30>.
69. Public Health England. NDNS: results from years 7-8 (combined). London: Public Health England; 2018. <https://www.gov.uk/government/statistics/ndns-results-from-years-7-and-8-combined>. Accessed 11 June 2022.
70. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. *Am J Epidemiol*. 2017;186:1026–34. <https://doi.org/10.1093/aje/kwx246>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

